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Abstract
It has been suggested that patients with motor neurone disease (MND) and those with MND combined with
behavioural variant frontotemporal dementia (bvFTD) (ie FTD + MND) or with FTD alone might exist on a
continuum based on commonalities of neuropathology and/or genetic risk. Moreover, it has been reported that
both a neuronal and a glial cell tauopathy can accompany the TDP-43 proteinopathy in patients with motor
neurone disease (MND) with cognitive changes, and that the tauopathy may be fundamental to disease
pathogenesis and clinical phenotype. In the present study, we sought to substantiate these latter findings, and test
this concept of a pathological continuum, in a consecutive series of 41 patients with MND, 16 with FTD +MND and
23 with FTD without MND. Paraffin sections of frontal, entorhinal, temporal and occipital cortex and hippocampus
were immunostained for tau pathology using anti-tau antibodies, AT8, pThr175 and pThr217, and for amyloid β
protein (Aβ) using 4G8 antibody. Twenty four (59 %) patients with MND, 7 (44 %) patients with FTD +MND and 10
(43 %) patients with FTD showed ‘significant’ tau pathology (ie more than just an isolated neurofibrillary tangle or a
few neuropil threads in one or more brain regions examined). In most instances, this bore the histological
characteristics of an Alzheimer’s disease process involving entorhinal cortex, hippocampus, temporal cortex, frontal
cortex and occipital cortex in decreasing frequency, accompanied by a deposition of Aβ up to Thal phase 3,
though 2 patients with MND, and 1 with FTD did show tau pathology beyond Braak stage III. Four other patients
with MND showed novel neuronal tau pathology, within the frontal cortex alone, specifically detected by pThr175
antibody, which was characterised by a fine granular or more clumped aggregation of tau without neurofibrillary
tangles or neuropil threads. However, none of these 4 patients had clinically evident cognitive disorder, and this
type of tau pathology was not seen in any of the FTD +MND or FTD patients. Finally, two patients, one with MND
and one with FTD, showed a tau pathology consistent with Argyrophilic Grain Disease (AGD). Western blotting and
use of 3- and 4-repeat tau antibodies confirmed the histological interpretation of Alzheimer’s disease type
pathology in all instances except for those patients with accompanying AGD where a banding pattern on western
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blot, and immunohistochemistry, confirmed 4-repeat tauopathy. In all 3 patient groups, amyloid pathology was
more likely to be present in patients dying after 65 years of age, and in the presence of APOE ε4 allele. We
conclude that tau pathological changes are equally common amongst patients with MND, FTD + MND and FTD
though, in most instances, these are limited in extent. In patients with MND, when cognitive impairment is present
this is most likely due to an accompanying/evolving (coincidental) Alzheimer’s disease process or, as in a single
case, Dementia with Lewy bodies, within the cerebral cortex rather than as a result of TDP-43 proteinopathy.
Conversely, in FTD and FTD +MND dementia is more likely to be associated with TDP-43 proteinopathy than tau.
Hence, present study shows no progression in severity of (tau) pathology from MND through FTD +MND to FTD,
and does not support the concept of these conditions forming a continuum of clinical or pathological change.
Introduction
Motor Neurone Disease (MND), also known as Amyo-
trophic Lateral Sclerosis (ALS), is classically described as a
neurodegenerative disorder of the locomotor system, char-
acterised by degeneration and loss of upper and lower
motor neurones, leading to a progressive weakness and
wasting of limb, bulbar and trunk musculature, with death
usually occurring within 2–3 years of symptom onset [3].
It affects 2–3 people in 100,000 worldwide, males slightly
more than females. While about 90 % of cases appear to
be sporadic in nature, with no known genetic cause, at
least 6 genes are implicated in the pathogenesis of the
remaining 10 % of familial cases [3]. These, in order of fre-
quency, are expansions in C9orf72, and point mutations in
SOD-1, FUS, TARDBP, UBQLN1 and VAPB genes. In
histological terms, all sporadic, and most familial cases
(those associated with C9orf72, TARDBP, UBQLN1 or
VAPB), are characterised by the presence of neuronal
cytoplasmic inclusions (NCI) within spinal and brainstem
motor neurones composed of the TAR DNA binding pro-
tein of 43KDa, TDP-43, whereas cases associated with mu-
tations in SOD-1 and FUS display NCI within these same
cell types containing these respective proteins [3].
However, MND is becoming increasingly recognised as
a multisystem disorder in which behavioural changes and
cognitive deficits can occur [12]. Cognitive change, par-
ticularly in executive functions, has been reported in up to
half of patients [19, 28]. Of these, about 10–15 % patients
fulfil criteria for behavioural variant frontotemporal de-
mentia (bvFTD) [13, 28]. In keeping with the pattern of
cognitive change, frontal lobe abnormalities have been
demonstrated in MND both on structural [2, 17] and
functional [1, 18] imaging. bvFTD may precede, follow or
coincide with the onset of motor symptoms [24], reinfor-
cing the inter-relationship between the two disorders.
The pathological substrate of dementia in MND, when
combined clinically with bvFTD (henceforth termed
FTD +MND), has been consistently linked to TDP-43
rather than tau pathology [4, 26]. However, the basis for
changes underlying cognitive deficits in MND, which do
not match up to fully fledged bvFTD, remains unclear. It
is of interest, therefore, that in a recent study, Yang and
Strong [36] found evidence of both TDP-43 and tau path-
ology in MND patients with and without cognitive impair-
ment. These authors employed novel tau polyclonal
antibodies to investigate tau pathology in 10 patients with
clinically and pathologically confirmed Amyotrophic
Lateral Sclerosis (ALS) (aka MND). Five showed cognitive
impairment (ALSci), as defined by Strong [31], whereas
five showed no cognitive impairment. In patients with
ALS alone, an antibody directed against tau phosphory-
lated at Thr175 (pThr175) detected limited neuronal tau
aggregates predominantly within entorhinal cortex and
amygdala, whereas an antibody directed against tau phos-
phorylated at Thr217 (pThr217) detected astrocytic tau de-
position in frontal cortex as well as in entorhinal cortex
and amygdala. In patients with ALSci, a more extensive
spread of neuronal pThr175 was seen, involving the frontal
lobe, whereas for pThr217 a more extensive astrocytic
involvement than in MND alone was observed. These
findings prompted Yang and Strong [34] to suggest that in
patients with MND with cognitive changes, a coincidental
tau and TDP-43 pathology is present, and that widespread
(astrocytic) tau pathology may be fundamental to patho-
genesis. Furthermore, Bieniek et al [6] noted excessive tau
pathology in a higher proportion of patients with FTLD-
TDP associated with an expansion in C9orf72, and in
others with FTLD-TDP with no known mutation, when
compared to cases of FTLD-TDP with GRN mutations
and suggested that some forms of TDP-43 proteinopathy
might favour or promote the development of tauopathy.
Hence, the overlap between TDP-43 and tau pathologies
in ALS [36] and FTLD [6], and the more marked tau
pathology in patients with MND with, rather than
without, cognitive impairment [36], could be interpreted
as supporting the spectrum/continuum notion of the
relationship between ALS and bvFTD.
If this were so, it might be postulated that the clinical
combination of FTD+MND could be driven in either dir-
ection from FTD or from MND through a common patho-
genetic pathway. By this argument, it might be anticipated
that tauopathy in MND would be exacerbated in FTD+
MND, and even more so in FTD. In order to test this hy-
pothesis we have used the same tau polyclonal antibodies
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used by Yang and Strong [36] to evaluate tau pathology in
an independent cohort of patients with MND, as well as in




The study group consisted of 80 patients, 41 with a clin-
ical diagnosis of MND (27 males, 14 females; patients
#1–41), 16 clinically diagnosed with FTD +MND (10
males, 6 females; patients #42–57) and 23 patients with
FTD but without MND (15 males, 8 females; patients
#58–80) (Table 1). Fifteen of the FTD group of patients
had a predominantly bvFTD phenotype whereas the
other 8 patients had a predominant language phenotype
(Table 1); for purposes of comparison all were subsumed
under the rubric of FTD without MND. Notably, all 23
patients within this FTD group shared a common TDP-
43 histological phenotype (see below). No patients were
available in which the clinical syndromes of Progressive
Non-Fluent Aphasia (PNFA) or Semantic Dementia were
combined with MND. The brains of these patients were
consecutively acquired by the Manchester Brain Bank
over the years 1986 to 2015. All patients were from the
North West of England and North Wales and tissues
were obtained through appropriate consenting proce-
dures for the collection and use of the human brain
tissues. The 16 patients with FTD +MND and the 23
patients with FTD without MND fulfilled relevant
clinical diagnostic criteria [14, 25, 27]. They had all been
investigated longitudinally within a specialist dementia
clinic using the Manchester Neuropsychological Profile
(Man-NP) [30, 34] to determine and characterise the
nature of their dementia. Some of the MND patients
had also undergone this formal neuropsychological
assessment, though in most others where this had not
been performed the presence of cognitive impairment
was deduced (in patients #35 and 36) from inspection of
clinical notes and medical correspondence by specialist
neuropsychologists. All 41 patients with MND fulfilled
El Escorial criteria [9].
Comparison of the three patient groups showed no
significant differences in gender distribution (χ2 = 0.095,
p = 0.953) or mean age at onset of disease (F2,65 = 0.89,
p = 0.416). However, mean age at death and duration of
illness did differ (F2,65 = 6.0, p = 0.004, F2,65 = 33.8, p <
0.001, respectively). Patients with FTD alone died at a later
age than those with MND (p = 0.003) and both patients
with MND, and those with FTD+MND, had a shorter
disease duration than those with FTD alone (p < 0.001),
though those with MND and FTD +MND did not differ
in this respect (Table 2).
Four patients with MND (patients #10, 14, 30 and 38),
4 with FTD +MND (patients #44, 53, 54 and 56) and 7
with FTD (patients #58, 71–74, 77 and 80) bore an ex-
pansion in C9orf72, as evidenced by Southern blot and/
or repeat primed PCR [11, 20] (Table 1). Twelve of the
other patients with FTD (patients #59–66, 69, 70, 75
and 76) bore mutation in progranulin gene (GRN). No
mutation was known to be present in the remaining 4
patients (patients # 67, 68, 79 and 80) (Table 1). There
were no significant differences between age at onset
(F2,65 = 0.158, p = 0.854) or age at death (F2,65 = 2.10, p =
0.130) between carriers of GRN mutation, C9orf72 ex-
pansion or those with no known mutation, though dur-
ation of illness did vary significantly between the three
groups (F2,65 = 21.2, p < 0.001) with bearers of GRN mu-
tation having a significantly longer disease course than
either those with C9orf72 expansion or those without
known mutation (p < 0.001 in both instances), which did
not differ from each other (p = 0.140) (Table 2).
Previous pathological diagnostic investigations had
shown all MND and FTD +MND patients to display at-
rophy and loss of motor neurones from trigeminal and
hypoglossal cranial nerve nuclei, and anterior horn cells
(where spinal cord was available), with the presence of
skein-like, or rounded, more solid, TDP-43 immuno-
reactive neuronal cytoplasmic inclusions (NCI) within
surviving cells, or with fine, particulate accumulations of
TDP-43, in which the nucleus has been ‘cleared’ of its
normal immunoreactivity Additional file 1: Figure S1.
Patient #35 with MND also had isocortical DLB [22],
along with Alzheimer-type pathology, though typical
TDP-43 pathology was still seen in anterior horn cells of
the spinal cord (see Additional file 1: Figure S1). Thirty
four MND patients showed no extramotor TDP-43 path-
ology at all, whereas 7 MND patients showed occasional
or moderate numbers of NCI within dentate gyrus granule
cells, four of whom also displayed moderate numbers of,
or many, TDP-43 immunopositive granules within the
cytoplasm of small pyramidal cells of layer II of the frontal
and temporal cortex, though well-formed NCI were only
rarely present. On the other hand, all 16 patients with
FTD+MND showed widespread TDP-43 immunoreactive
NCI within hippocampal dentate gyrus granule cells and
numerous cells in layer II of the frontal and temporal cor-
tex contained TDP-43 immunopositive granules with
well-formed NCI in others, in the relative absence of
TDP-43 immunoreactive neurites, consistent with neuro-
pathological classification of FTLD-TDP type B [20].
Additionally, there was loss of motor neurones from tri-
geminal and hypoglossal cranial nerve nuclei, and anterior
horn cells (where spinal cord was available) with TDP-43
immunoreactive NCI within surviving cells. Conversely,
all 23 patients with FTD alone showed numerous TDP-43
immunoreactive NCI and neurites in layer II of the frontal
and temporal cortex with variable numbers of TDP-43 im-
munoreactive NCI in granule cells of the dentate gyrus of
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1 na MND unknown MND F 56 57 1 na N na 0 0
2 na MND unknown MND F 50 52 2 na N na 0 0
3 na MND unknown MND M 77 77 0.5 na N na 0 0
4 na MND unknown MND M na na na na na na 0 0
5 na MND unknown MND M na na na na na na 0 0
6 na MND unknown MND M na na na na na na 0 0
7 BBN_3043 MND unknown MND M 42 45 2 33 N none 0 0
8 BBN_3068 MND normal MND M 60 63 3 na N na 0 0
9 BBN_3158 MND unknown MND M na na na 33 N none 0 0
10 BBN_3340 MND normal MND M 43 45 2 33 Y C9orf72 0 0
11 BBN_3436 MND normal MND M 49 51 2 33 N none 0 0
12 BBN_6065 MND normal MND M 53 55 2 33 N none 0 0
13 BBN_18408 MND normal MND M 40 46 6 34 N none 0 0
14 BBN_24300 MND normal MND M 55 58 3 33 N C9orf72 0 0
15 na MND unknown MND F 69 71 2 na N na 3 0
16 na MND unknown MND F na na na na na na 1 0
17 BBN_3307 MND normal MND M 66 72 6 33 N none 1 0
18 na MND unknown MND M 42 44 ? na N na 0 0-I
19 BBN_3106 MND unknown MND F 72 76 4 33 N none 0 0-I
20 BBN_3268 MND normal MND M na na na 33 N none 0 0-I
21 BBN_3317 MND normal MND M na na na 33 N none 0 0-I
22 BBN_3429 MND normal MND M 50 52 2 34 N none 0 0-I
23 BBN_3456 MND normal MND F 55 57 2 23 N none 0 I
24 BBN_10257 MND unknown MND M 74 77 3 33 N none 0 I
25 BBN_3315 MND normal MND M 65 67 2 33 N none 0 I
26 BBN_24685 MND normal MND F 53 58 5 34 N none 0 I
27 BBN_3319 MND normal MND F na na na 33 N none 3 0-I
28 BBN_3330 MND normal MND F na na na 33 N none 2 0-I
29 na MND unknown MND M na na na na na na 3 I
30 BBN_3212 MND normal MND M 60 65 5 34 Y C9orf72 3 I-II
31 BBN_3341 MND normal MND F 83 85 1.5 34 N none 5 I-II
32 BBN_3342 MND normal MND F 65 67 2 33 N none 3 I-II
33 na MND unknown MND M na na na na na na 3 II
34 BBN_25502 MND normal MND F 73 76 3 33 N none 3 II
35 BBN_13803 MND dementia MND F 65 69 4 23 N none 3 IV
36 BBN_3297 MND cognitive impaired MND F na na na 33 N none 3 IV-V
37 BBN_3004 MND normal MND M 43 47 4 na N na 0 na
38 BBN_3344 MND normal MND M 55 57 2 33 Y C9orf72 0 na
39 BBN_3418 MND normal MND F 37 39 2 33 N none 0 na
40 BBN_6078 MND normal MND M 46 52 4 34 N none 2 na
41 BBN_3457 MND normal MND M 60 63 3 33 N none 0 na
42 BBN_5658 FTD+MND dementia FTLD-TDP B M 45 47 2 na N na 0 0
43 BBN_5661 FTD+MND dementia FTLD-TDP B M 43 45 2 34 N none 0 0
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the hippocampus, consistent with pathological classifica-
tion of FTLD-TDP type A [20]. Additionally, those pa-
tients bearing GRN mutations showed variable presence
of TDP-43 immunoreactive neuronal intranuclear inclu-
sions (NII) in neurones of layer II of frontal and temporal
cortex, but these were not seen in those patients bearing
expansion in C9orf72, or in the 4 cases without known
mutation. Dipeptide repeat proteins consisting of poly-
GA, poly-GP and poly-GR proteins were present in CA4
neurones of hippocampus and granule cells of the dentate
gyrus and cerebellum in all 16 C9orf72 expansion bearers,
irrespective of clinical phenotype [11].
Immunohistochemistry
Paraffin sections were cut at 6 μm from formalin fixed
blocks of frontal lobe (BA8/9), temporal lobe (BA21/22)
Table 1 Selected clinical, neuropathological and genetic details on patients studied (Continued)
44 BBN_5663 FTD+MND dementia FTLD-TDP B M 57 59 2 33 Y C9orf72 0 0
45 BBN_5669 FTD+MND dementia FTLD-TDP B M 65 67 2 33 N none 0 0
46 BBN_5732 FTD+MND dementia FTLD-TDP B F 50 52 3 34 Y none 0 0
47 BBN_3334 FTD+MND dementia FTLD-TDP B M na na na 33 N none 0 0
48 BBN_3459 FTD+MND dementia FTLD-TDP B F 61 63 2 33 N none 0 0
49 BBN_10258 FTD+MND dementia FTLD-TDP B M 61 64 3 33 N none 0 0
50 BBN_14791 FTD+MND dementia FTLD-TDP B M 72 75 3 34 N none 0 0
51 BBN_24314 FTD+MND dementia FTLD-TDP B F 59 63 4 33 N none 0 0-I
52 BBN_5764 FTD+MND dementia FTLD-TDP B M 61 65 4 33 N none 0 0-I
53 BBN_5772 FTD+MND dementia FTLD-TDP B F 70 73 3 33 Y C9orf72 0 0-I
54 BBN_24359 FTD+MND dementia FTLD-TDP B M 51 58 7 33 Y C9orf72 0 0-I
55 BBN_24376 FTD+MND cognitive impaired FTLD-TDP B F 78 79 1 34 N none 0 0-I
56 BBN_5771 FTD+MND dementia FTLD-TDP B F 63 65 2 33 Y C9orf72 0 I
57 BBN_5721 FTD+MND dementia FTLD-TDP B M 58 69 11 33 N none 1 I
58 BBN_5681 FTD dementia FTLD-TDP A M 49 58 9 33 Y C9orf72 0 0
59 BBN_5705 FTD dementia FTLD-TDP A F 53 67 14 33 Y V452WfsX38 0 0
60 BBN_10260 PNFA dementia FTLD-TDP A M 62 72 10 33 Y V452WfsX38 0 0
61 BBN_5660 FTD dementia FTLD-TDP A F 53 71 18 33 Y V452WfsX38 0 0
62 BBN_5773 FTD dementia FTLD-TDP A M 66 73 7 33 Y Q130SfsX124 0 0
63 BBN_5715 PNFA dementia FTLD-TDP A F 63 71 8 33 Y Q130SfsX124 0 0
64 BBN_5718 FTD dementia FTLD-TDP A M 59 66 7 33 Y R493X 0 0
65 BBN_5675 FTD dementia FTLD-TDP A F 51 61 10 na Y R493X 0 0
66 BBN_5686 FTD dementia FTLD-TDP A F 60 66 6 33 N Q468X 0 0
67 BBN_5734 FTD dementia FTLD-TDP A M 69 75 6 33 N none 0 0
68 BBN_5757 PNFA dementia FTLD-TDP A F 66 77 11 33 N none 0 0
69 BBN_5666 PNFA dementia FTLD-TDP A M 55 71 16 34 Y V452WfsX38 2 0
70 BBN_5677 PNFA dementia FTLD-TDP A M 62 70 8 34 Y V452WfsX38 2 0
71 BBN_5719 FTD dementia FTLD-TDP A F 59 64 5 33 Y C9orf72 0 0-I
72 BBN_5752 FTD dementia FTLD-TDP A M 64 72 8 33 Y C9orf72 0 0-I
73 BBN_5739 FTD dementia FTLD-TDP A M 62 67 5 33 Y C9orf72 0 0-I
74 BBN_14793 FTD dementia FTLD-TDP A M 54 65 11 33 Y C9orf72 0 0-I
75 BBN_5727 PNFA dementia FTLD-TDP A M 66 73 7 33 Y C31LfsX34 0 0-I
76 BBN_5742 PNFA dementia FTLD-TDP A M 66 71 5 34 Y V452WfsX38 0 I
77 BBN_5774 FTD dementia FTLD-TDP A M 63 65 2 34 Y C9orf72 2 0-I
78 BBN_5706 FTD dementia FTLD-TDP A M 60 68 8 34 Y C9orf72 2 0-I
79 BBN_5685 PNFA dementia FTLD-TDP A M 68 78 10 34 N none 3 IV-V
80 BBN_5753 FTD dementia FTLD-TDP A F 66 72 6 33 N none 3 I-II
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including anterior and posterior hippocampus and ento-
rhinal cortex, occipital lobe (BA17/18), corpus striatum
and cerebellum from all individuals. We did not include
sections from ‘neighboring’ areas such as insular and
cingulate cortex into the study as previous diagnostic
neuropathological analyses had not revealed these to be
different (in terms of tau pathology) from chosen areas
of temporal and frontal cortex, respectively. Following
titration to determine optimal immunostaining, antibodies
were identically employed in a standard IHC protocol, as
described previously [11, 21]. Frontal, temporal (to include
hippocampus and entorhinal cortex) and occipital lobe sec-
tions were immunostained for tau proteins. The following
tau antibodies were employed: AT8 (1:750), pThr175 and
pThr217 (both of which were used at 1:1000 dilution). These
latter antibodies are polyclonal phospho-tau antibodies
generated against sequences Ac-SLP[pT]PPTREPC-amide
and Ac-RIPAK[pT]PPAPKC-amide, respectively. Full details
regarding the production and specificity of these antibodies
have been presented elsewhere [36]. Negative controls
omitting pThr175 and pThr217 antibody, and normal brain
sections known to be free from tau pathology using AT8
antibody were employed to substantiate the specificity of
pThr175 and pThr217 antibodies. Selected sections of frontal
and temporal cortex (see later) were immunostained for 3-
repeat (3-R) and 4-repeat (4-R) tau proteins using RD3 and
RD4 antibodies (Millepore), at a dilution of 1:1500 and
1:200, respectively. For each tau antibody, antigen unmasking
was performed by pressure cooking in citrate buffer (pH 6.0,
10 mM) for 30 min, reaching 120° Celsius and >15 kPa pres-
sure. Additional sections of frontal, temporal (to include
hippocampus and entorhinal cortex) and occipital cortex,
along with those of corpus striatum and cerebellum, were
immunostained for amyloid plaques using 4G8 antibody
(1:3000). Antigen retrieval was in this case performed by
immersion in 95 % formic acid for 5 min prior to incubation
in primary antibody. Sections of frontal and temporal cortex
were also immunostained for TDP-43 and phosphorylated
α-synuclein as above.
AT8, pThr175 and pThr217 immunostained sections
were scored microscopically at an objective magnifica-
tion of x25 (overall magnification of x250) for the
presence and severity of tau pathological changes, as
visualised by each of the tau antibodies, employing the
following rating scale:
0 = No tau pathology present.
0.5 = rare (ie 1–5 tau immunoreactive neurofibrillary
tangles/neurites per section.
1 = 1–5 tau immunoreactive neurofibrillary tangles/
neurites per x250 microscope field.
2 = 5–10 tau immunoreactive neurofibrillary tangles/
neurites per x250 microscope field.
3 = more than 10 tau immunoreactive neurofibrillary
tangles/neurites per x250 microscope field.
Cases were also assessed for the extent and distribu-
tion of neurofibrillary (AT8) and amyloid plaque (4G8)
pathology, employing Braak and Braak [7] and Thal [33]
staging procedures, respectively. Cases where no tau
pathology whatsoever was present were staged 0,
those where only rare neurofibrillary tangles were
present in entorhinal cortex alone were staged 0-I. Stage
I cases showed abundant tangles in entorhinal cortex
Table 2 Mean (±SD) values for age at onset of symptoms, age at death and duration of illness for patients with Motor Neurone
Disease (MND), behavioural variant Frontotemporal Dementia and Motor Neurone Disease (FTD +MND) and FTD. Also shown are
mean (±SD) values for age at onset of symptoms, age at death and duration of illness for those cases of MND, FTD +MND and FTD,
collectively, with mutations in GRN, expansion in C9orf72, or no known mutation, along with mean (±SD) values for age at onset of
symptoms, age at death and duration of illness for those cases of MND, FTD + MND and FTD, collectively, showing with and without
amyloid pathology, and those with and without (any type of) tau pathology
Group Age at onset (y) Age at death (y) Duration of illness (y)
MND (n = 41) 57.2 ± 12.2 60.1 ± 12.0* 2.9 ± 1.4**
FTD +MND (n = 16) 59.8 ± 9.4 63.1 ± 9.4 3.4 ± 2.4**
FTD (n = 23) 60.7 ± 5.7 69.3 ± 4.9 8.8 ± 3.7
GRN mutation (n = 12) 59.7 ± 5.5 69.3 ± 3.6 9.7 ± 4.2
C9orf72 expansion (n = 15) 57.7 ± 7.1 62.9 ± 7.1 5.2 ± 3.0!!!
No genetic mutation (n = 53) 59.2 ± 11.4 62.7 ± 11.8 3.5 ± 2.4!!!
All cases with amyloid (n = 21) 64.2 ± 8.1$$ 70.0 ± 7.2$$$ 5.8 ± 4.2
All cases without amyloid (n = 59) 57.5 ± 9.8 62.2 ± 10.4 4.7 ± 3.5
All cases with tau (n = 41) 60.7 ± 10.4 65.1 ± 10.5 4.4 ± 2.7
All cases without tau (n = 39) 57.4 ± 9.0 60.7 ± 10.4 5.4 ± 4.4
*, ** indicate significantly different from FTD group, p = 0.003 and p < 0.001, respectively
!!! indicates significantly different from GRN mutation group, p < 0.001
$$, $$$ indicate significantly older than cases without amyloid, p = 0.003, <0.001, respectively
Behrouzi et al. Acta Neuropathologica Communications  (2016) 4:33 Page 6 of 16
alone [see 7]. Neuritic plaques were rated according to
CERAD criteria.
Western blotting
200–500 mg samples of frozen frontal and temporal
cortex were dissected from selected tau-immunopositive
cases (see later) and subjected to western blot analysis of
insoluble tau, as we have described elsewhere [32].
Briefly, sarkosyl-insoluble pellets were prepared by
homogenization of tissue samples in 20vol (v/w) of
extraction buffer containing 10 mM Tris–HCl (pH 7.5),
0.8 M NaCl, 10 % sucrose, 1 mM EGTA, 2 % sarkosyl
and incubated for 30 min at 37 °C. After centrifugation
at 20,000 g for 10 min at 25 °C, the supernatants were
taken, transferred to 1.5 mL tubes and ultracentrifuged
at 100,000 g for 20 min at 25 °C. The pellets were
washed by ultracentrifugation with 0.5 mL of sterile sa-
line, solubilized in SDS-sample buffer and subjected to
4–20 % gradient polyacrylamide gel (Wako) SDSPAGE.
Proteins were transferred to PVDF membrane, incubated
overnight with the anti-tau monoclonal antibody T46
(Thermo Scientific), biotinylated 2nd antibody, avidin–
biotin complex (Vector) and developed with diamino-
benzidine and nickel chloride.
Statistical analysis
Comparisons of semiquantitative scores for severity of AT8,
pThr175 and pThr217 immunostaining in frontal and
temporal cortex, entorhinal cortex and CA1 region of hippo-
campus, were performed using Kruskal-Wallis test with
post-hoc Mann-Whitney test where Kruskal-Wallis yielded a
significant difference between antibody staining scores.
Comparisons of APOE ε4 allele frequency between MND,
FTD+MND and FTD groups, and cases of MND, FTD+
MND and FTD, collectively, with and without amyloid
deposition, were made using Chi squared test. Comparisons
of mean age at onset, age at death and duration of illness
between patients with MND, FTD+MND and FTD, with
and without amyloid deposition, were made using unpaired
t-test. Significance levels were set at p < 0.05 throughout.
All research reported in the paper was performed with
ethical approval under the Manchester Brain Bank
Generic Tissue Bank Ethics approved by Newcastle and
North Tyneside Ethics Committee.
Results
Tau immunostaining
Overall, when using the full panel of tau antibodies (ie AT8,
pThr175 and pThr217 antibodies), 17 (41 %) patients with
MND (patients #1–17), 9 (56 %) patients with FTD+MND
(patients #42–50) and 13 (56 %) patients with FTD alone
(patients #58–70) showed either no tau pathology at all, or
only isolated neuronal tau pathology, in any region of brain
examined. These 39 patients were classed as Braak stage 0.
Eleven patients (27 %) with MND (patients #18–25 and
#27–29), 7 patients (44 %) with FTD+MND (patients
#51–57) and 9 with FTD (39 %) showed sparse tau
neuronal pathology (ie a single or a few neurofibril-
lary tangles and/or a few neuropil threads per section,
usually only in a single brain region, and then most
often in the entorhinal cortex) with any, or all, of the
3 tau antibodies employed. These 27 patients were
classed as Braak stage 0-I/I.
The remaining 13 patients (31 %) with MND (patients
#26, 30–41) (but none with FTD +MND and only 1
with FTD (patient #79 with PNFA) displayed a ‘signifi-
cant degree of tau pathology’, as defined by the presence
of a few to many neurofibrillary tangles and/or neuropil
threads in several brain regions, usually with all 3 tau
antibodies and again usually to a similar extent and with
a similar distribution. Eight of these patients (patients
#26, 30–36 and 79) were classed as having Braak stages
II and greater. Seven patients (patients #30–36) showed
moderate to severe involvement of entorhinal cortex
with mild to severe involvement of CA1 region of hippo-
campus, but this was without neocortical involvement in
patients #30–34, consistent with Braak stages I-II/II.
The other 3 patients (patients #35, 36 and 79) (see Add-
itional file 2 for full clinical and neuropathological de-
tails of patient #35) also showed moderate or severe
involvement of inferior temporal gyri and superior
frontal cortex (Braak stage IV), and 2 of these (patients
#36 and 79) had some involvement of the visual associ-
ation cortex, but not primary visual cortex, consistent
with Braak stages IV-V. The pattern of tau pathology in
the remaining 5 MND patients (patients #37–41) was
such that it was not possible to Braak stage these cases
(see later). Patients with MND were no more, or no less,
likely to display some/any degree of tau pathology than
those with FTD +MND, or those with FTD (χ2 = 0.037,
p = 0.982).
Three major patterns of tau pathology were noted, and
patients were grouped accordingly. Group 1 tau staining
pattern was most common, irrespective of the actual
amount of staining present, being seen in 19 (of the 24 tau
positive) patients with MND (patients #18–36), in all 7
patients with FTD+MND (patients #51–57) and in 9 of
the patients with FTD (patients #71–79). The staining
pattern resembled that of an Alzheimer’s disease-type
process (Fig. 1a-f), with a few to many neurofibrillary tan-
gles and neuropil threads being present within entorhinal
cortex (in all 19 tau-positive patients with MND, all 7 tau-
positive patients with FTD+MND and all 10 tau-positive
patients with FTD), CA1 region of hippocampus (16/17
patients with MND, all 7 patients with FTD+MND and
8/9 patients with FTD), inferior and middle temporal gyri
(15/17 patients with MND, 4/7 patients with FTD+MND
and 5/9 patients with FTD), superior frontal cortex (9/17
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patients with MND, 1/5 patients with FTD +MND and 5/9
patients with FTD) and visual association cortex (1/17 pa-
tients with MND and 1/9 patients with FTD) (see Fig. 1).
Interestingly, 4 patients with MND patients (patients #19,
20, 25 and 26) also showed extensive CA2 tau pathology.
Group 2 tau staining pattern was seen in 4 patients
(patients #37–40) (Fig. 2). Here, there was occasional to
frequent tau immunostaining of neurones of superior
frontal cortex, and to a lesser extent inferior temporal
cortex, but no involvement of entorhinal cortex, occipi-
tal cortex or CA1 region of hippocampus, with pThr175
antibody: no such immunostaining was seen with either
AT8 or pThr217 antibodies. In contrast to the above
group of patients, the tau immunostaining appeared
either finely, or coarsely, granular with no neurofibril-
lary tangle-like structures, or neuropil threads, being
seen. Although one of the patients showing the group
2 form of tau pathology (patient #38) bore an expan-
sion in C9orf72, the tau pathology did not appear to
be specifically associated with this genetic change as
none of the other 3 patients with this tau particular
pathology bore an expansion in C9orf72, nor did any
of the other 7 expansion carriers display group 2 type
changes in tau.
In patients #41 (see Additional file 2 for full clinical and
neuropathological details) and 80 (group 3), a third
Fig. 1 Tau and amyloid pathology in MND Group 1 patients. Alzheimer-type tau pathology is present in CA1 region of hippocampus (a-c) and
entorhinal cortex (d-f) in patient #35 with MND and Dementia with Lewy bodies as shown by immunostaining for tau with AT8 (a and d),
pThr175 (b and e) and pThr217 (c and f) antibodies. Both diffuse (g) and cored (h) amyloid plaques are present with 4G8 antibody. Cerebral
amyloid angiopathy affecting capillaries (i) is present in patient #33. Immunoperoxidase x400
Fig. 2 Tau pathology in MND group 2 patients. Neuronal tau
pathology is present in frontal cortex in patient #38, and detected
by pThr175 antibody alone. Immunoperoxidase x400
Behrouzi et al. Acta Neuropathologica Communications  (2016) 4:33 Page 8 of 16
pattern of tau pathology was seen (Fig. 3). In this there
was mild neurofibrillary tangle formation in granule cells
of the dentate gyrus of the hippocampus, and in areas
CA3 and CA4. However, there was total involvement of
CA2 region with all cells being affected by neurofibrillary
tangles or containing amorphous tau but without apparent
cell loss. There was severe loss of cells from CA1 and subi-
culum, with severe hippocampal sclerosis, with the remain-
der containing neurofibrillary tangles. Likewise the
entorhinal cortex was severely affected (especially layer II
stellate cells) and this extended into layers III and V of the
adjoining inferior temporal gyrus, thinning out to minimal
involvement in superior temporal gyrus, and superior
frontal gyrus. In addition to the neuronal pathology, there
was dense oligodendroglial cell involvement in the form of
tangles resembling coiled bodies. These were most numer-
ous in white matter in entorhinal cortex and inferior tem-
poral gyrus, becoming infrequent in superior temporal and
superior frontal gyri. This pattern of tau pathology was con-
sistent with Argyrophilic Grain Disease (AGD).
In some patients, occasional glial cells, resembling
astrocytes, also showed some granular, or fibrillary, tau
immunoreactivity with all 3 tau antibodies, though for
the most part this did not adopt a consistent pattern,
nor was it present in anything but isolated cells. Notably,
we did not observe any specific immunostaining of glial
cells of the kind described by Yang and Strong [34] using
pThr217 antibody in any patient.
Comparisons between immunostaining with AT8, pThr175
and pThr217 antibodies
Semiquantitative scores for tau pathology, as detected by
AT8, pThr175 and pThr217 antibodies, were compared in
each of entorhinal cortex, CA1 region of hippocampus,
temporal and frontal neocortex by Kruskal-Wallis test. No
significant difference between the degree of tau antibody
staining was detected for CA1 region, entorhinal cortex,
temporal cortex, or frontal cortex either when all 80
patients were grouped together, or when split according to
clinical grouping (Table 3). Patients were also grouped ac-
cording to their pattern of tau pathology (as described
above) including, as group 4, those patients with no or iso-
lated tau (ie patients #1–17, #42–50 and #58–70). Again,
no significant difference between the degree of tau staining
with each of the three antibodies was detected for CA1 re-
gion, entorhinal cortex, temporal cortex, or frontal cortex
for tau groups 1, 3 and 4. However, for tau group 2 there
was a significant difference between the degree of tau anti-
body staining in frontal cortex (χ2 = 10.51, p = 0.005), but
not in the other 3 regions (Table 3). Post hoc analysis
showed that the level of tau staining was significantly
higher with pThr175 than with pThr217 (p = 0.029) or
Fig. 3 Tau pathology in Group 3 patients. Neuronal and neuritic plaque (a-c) tau pathology in CA1 region of hippocampus (a-c) and glial cell
(d-i) tau pathology in entorhinal cortex grey matter (d-f) and white matter (g-i) as shown by immunostaining with AT8 (a, d and g), pThr175
(b, e and h) and pThr217 (c, f and i) antibodies. Immunoperoxidase x400
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AT8 (p = 0.029) antibodies, but the latter 2 did not differ
significantly (p = 0.999), thereby bearing out microscopic
observations.
Tau isoform analysis
In order to further characterise the molecular nature of the
tau pathology present in each tau group, sections of frontal
and/or temporal cortex from selected patients (ie tau group
1, patients #23, 31, 35, 36, 53, 56, 78 and 80; tau group 2
patients #37–40; tau group 3, patients #41 and 79) were
subjected to immunostaining with 3-R (RD3) and 4-R
(RD4) tau antibodies. These patients were selected because
they showed the greatest levels of tau pathology within each
of their respective groups, and were therefore considered to
be most informative as regards the 3 patterns of tau path-
ology seen on AT8, pThr175 and pThr217 immunostaining.
Sections of temporal and frontal cortex from tau group 1
cases showed neurofibrillary tangles, neuropil threads
and neuritic plaques to be strongly immunoreactive
for 4-R tau (Fig. 4a, b) and also, but less intensely so,
for 3-R tau proteins (not shown). Sections of frontal
cortex from tau group 2 cases showed neurones to be
weakly immunoreactive for 3-R tau (not shown), but
more strongly for 4-R tau protein (Fig. 4c). In tau
group 3, there was strong 4-R tau immunostaining of
neurofibrillary tangles and amorphous tau (pretangle)
in cells of CA1 region, and amorphous tau staining in
CA2 neurones, with tangles also being present in some
CA2 cells (Fig. 4d). Tau grains were also strongly 4-R tau
immunoreactive (Fig. 4e), as were oligodendroglial cells
with coiled bodies in the adjoining white matter (Fig. 4f).
The well-formed neurofibrillary tangles in CA2 region
were also 3-R tau immunoreactive, but grains and glial
cells were negative for 3-R tau (not shown).
Table 3 Significance values for Kruskal-Wallis comparisons of degree of AT8, pThr175 and pThr217 tau immunostaining in CA1 region
of hippocampus, entorhinal cortex, temporal cortex and frontal cortex for all 80 patients, collectively or when stratified according to
clinical phenotype, or tau pathological profile
Group CA1 Entorhinal cortex Temporal cortex Frontal cortex
All cases (n = 80) 0.726 0.544 0.834 0.877
MND (n = 41) 0.758 0.518 0.963 0.371
FTD +MND (n = 16) 0.675 0.577 0.231 0.993
FTD (n = 23) 0.935 0.753 0.717 0.544
Tau group 1 (n = 35) 0.621 0.607 0.759 0.539
Tau group 2 (n = 4) 1.000 0.368 0.113 0.005
Tau group 3 (n = 2) 0.535 0.852 0.275 0.882
bolded figures indicate significant difference in staining between the three anti-tau antibodies
Fig. 4 Neurofibrillary tangles and neuropil threads in entorhinal (a) and frontal (b) cortex in MND tau group 1 patients are immunoreactive for
both 3-R (not shown) and 4-R tau (a, b) proteins. Amorphous tau deposits in neurones of frontal cortex in MND tau group 2 patients (patient
#38) are 4-R (c), but not 3-R tau (not shown) immunoreactive. Neurofibrillary tangles and amorphous tau deposits in CA2 neurones in MND tau
group 3 patients are both 4-R tau immunoreactive (d). Neurofibrillary tangles are also 3-R tau immunoreactive (not shown). Argyrophilic grains in
CA1 region of hippocampus (e) and oligodendroglial tangles in underlying white matter (f) are both immunoreactive for 4-R tau (e, f) but not 3-R
tau (not shown). Immunoperoxidase, x400 microscope magnification
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Where available, frozen tissue samples of frontal and/or
temporal cortex were taken from selected patients in each
tau group (group 1, patients #23, 26, 30, 31, 34, 35, 55 and
80; group 2, patients #39 and 40; group 3, patient #41)
and subjected to western blot analysis. Unfortunately, in
most patients the amount of insoluble tau extractable
from the tissue samples was too low to detect on blotting,
even on 5-fold enrichment of applied sample. However, in
patients #30 and 35 (tau group 1), 40 (tau group 2) and 41
(tau group 3) clear banding patterns were obtained from
temporal, but not frontal, cortical samples which enabled
molecular classification of the pathological tau proteins
present (Fig. 5). Patients #30, 35 and 40 (lanes 1–3)
showed an Alzheimer’s disease-like triplet banding pattern
comprising bands of hyperphosphorylated full-length tau
at 60, 64 and 68 kDa, though various C-terminal frag-
ments and smears were also detected. In contrast, the
banding pattern in patient #41 with AGD (lane 4) is char-
acteristic of 4-repeat tauopathy with major bands at 64
and 68 kDa.
Amyloid (4G8) immunostaining
On 4G8 immunostaining, 27 (66 %) patients with MND
(patients #1–14, 18–26, 37–39 and 41, 15 (93 %) patients
with FTD+MND (patients #42–56) and 17 (74 %) with
FTD (patients # 58–68 and 71–76) showed no amyloid
plaque pathology whatsoever in any brain region examined.
Conversely, 14 (34 %) patients with MND (patients #15–17,
27–36 and patient #40) 1 (7 %) patient with FTD+MND
(patient #57) and 6 (26 %) patients with FTD (patients #69,
70 and 77–80) displayed some degree of amyloid plaque
pathology, however minimal. As with tau pathology, pa-
tients with MND were no more likely to display some
amyloid plaque pathology than those with FTD+MND or
FTD (χ2 = 4.25, p = 0.119). In 8 patients with MND (pa-
tients #16, 17, 27–30 and 40) and 2 with FTD (patients #
69 and 70) amyloid plaques were mostly or exclusively
present as diffuse amyloid plaques, and only rare cored/
neuritic plaques were generally present. Only in 6 patients
with MND (patients #17, 31, 33–36) and 4 with FTD
(patients #77–80) were neuritic plaques more widespread.
Hence, the former 8 patients with MND and 2 with FTD
were classed as A by CERAD criteria, the latter 6 with
MND and 4 with FTD were classed as B. The single patient
with FTD+MND showing amyloid pathology (patient #57)
was classed as CERAD A.
Of the 14 patients with MND showing amyloid plaque
pathology, two patients (patients #16 and 17) showed
only mild neocortical involvement (usually temporal cor-
tex, maximally) consistent with Thal phase 1. Two
others (patients #28 and 40) showed allocortical involve-
ment, consistent with Thal phase 2. Eight patients
(patients #15, 27, 29, 30, 32–36) additionally showed
amyloid deposition in the striatum (Thal phase 3) and
one (patient#31) also showed brain stem and cerebellar
involvement (Thal phase 5). The single patient with
FTD +MND (patient #57) showed amyloid pathology at
Thal phase 1. Of the 6 patients with FTD showing
amyloid plaque pathology, four patients (patients #69,
70, 77 and 78) showed only mild to moderate neocor-
tical involvement with mild allocortical involvement,
consistent with Thal phase 2. The remaining 2 patients
(patients #79 and 80) additionally showed mild amyloid
deposition in the striatum (Thal phase 3), but neither
also showed brain stem or cerebellar involvement.
Cerebral amyloid angiopathy (CAA) was generally
absent in all 3 diagnostic groups, totally so in the FTD +
MND group and affecting only a single patient in the
FTD group). Occasional leptomeningeal arteries were af-
fected in 4 MND patients (patients #15, 16, 29 and 36)
though in 3 other MND patients (patients #17, 31 and
33) and the FTD patient with PNFA phenotype (patient
#79) leptomeningeal CAA was more extensive, particu-
larly in the occipital cortex, and in one of these (patient
#33) this also involved capillaries within the primary
Fig. 5 Immunoblot analysis of sarkosyl-insoluble tau extracted from
temporal cortex, and detected by T46 (anti-tau C-terminus) antibody.
MND tau group 1 (patients #30 and 35) (lanes 1 and 2, respectively)
and group 2 (patient #40) (lane 3) show an Alzheimer’s disease-like
triplet banding pattern comprising bands of hyperphosphorylated
full-length tau at 60, 64 and 68 kDa, though various C-terminal
fragments and smears are also detected. In contrast, the banding
pattern in MND tau group 3 patients (patient #41) with Argyrophilic
Grain Disease (lane 4) is characteristic of 4-R tauopathy with major
bands at 64 and 68 kDa
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visual cortex. In patient #79, cerebellar arteries were also
affected.
AT8 and 4G8 immunostaining
Fourteen of 41 patients with MND (34 %) (patients #1–
14), 9/16 with FTD +MND (56 %) (patients #42–52)
and 11/23 (48 %) patients with FTD (patients #58–68)
showed neither amyloid nor tau pathology in any region
of the brain examined. However, 11/41 (27 %) MND
(patients #27–36 and patient #40) showed some degree
of both tau and amyloid plaque pathology. Two of the
patients (patients #28 and 40) showed Thal phase 2
amyloid plaque pathology, one of whom was Braak stage
0-I (patient #28), whereas the other (patient #40) was
not classifiable by Braak staging. Eight other patients
showed Thal phase 3 amyloid plaque pathology of which
1 patient was Braak stage 0-I, 1 was Braak stage I, 2 were
Braak stage I-II, 2 were Braak stage II, 1 was Braak stage
II-III and 1 was Braak stage V. Only 1 patient had a Thal
phase greater than 3 (patient #31), but here Braak stage
was only I-II. The single patient with FTD +MND show-
ing both tau and amyloid plaque pathology (patient #57)
was Thal phase 1 and Braak stage 1. Of the 4 patients
with FTD with both tau and amyloid pathology (patients
#77 and 78) were Thal phase 2, Braak stage 0-I, 1 (patient
#80) was Thal phase 3, Braak stage I-II and the other
(patient #79) was Thal phase 3, Braak stage IV-V.
Consequently, there were 13 patients with MND
(patients #18–26, 37–39 and 41), 6 patients with FTD +
MND (patients #51–56) and 6 patients with FTD (patients
#71–76) that showed some degree of tau pathology but no
amyloid plaque pathology at all. All of these were at Braak
stage 0-I/I except patient #41 where no Braak classifica-
tion was possible. Conversely, there were 3 patients with
MND (patients #15–17) and 2 with FTD (patients #69
and 70) who showed amyloid plaque formation without
tau pathology, 2 being at Thal phase 1 (patients #15 and
16) and 3 being at Thal phase 2 (patients #15, 69 and 70).
Amyloid, tau, age and Apolipoprotein E (APOE) genotype
Where relevant age at onset and death data was available,
patients with MND, MND+ FTD or FTD, collectively,
showing amyloid plaque formation were significantly
older, both at onset (p = 0.003) and at death (p = 0.001),
than those not showing amyloid plaque formation.
However, duration of illness did not differ between each
group (p = 0.343) (Table 2). By contrast, there were no sig-
nificant differences between patients with MND, MND+
FTD or FTD, collectively, showing any type of tau path-
ology and those without tau pathology at all, for age
at onset (p = 0.493), age at death (p = 0.726) or
duration of illness (p = 0.364) (Table 2).
APOE genotype was only available for 65/80 patients.
Overall, the APOE ε4 allele frequency was 12.5 % (16/
128 alleles), and was not significantly different in MND
(10.7 %, 6/56 alleles), FTD +MND (13.3 %, 4/30 alleles)
or FTD (13.6 %, 6/44 alleles (χ2 = 0.232, p = 0.890),
although the APOE ε4 allele frequency in those patients
with MND, FTD +MND and FTD, collectively, showing
amyloid plaque formation (20 %, 8/40 alleles) tended to
be significantly greater (χ2 = 3.17, p = 0.075) than in
those without amyloid (8.9 %, 8/90 alleles).
Nonetheless there was a significant effect of age. Irre-
spective of APOE genotype, 14 of the 15 patients show-
ing amyloid plaques were all over 65 years of age at
death. Conversely, only 23 of the 53 patients without
amyloid were over 65 years of age at death, and of these
only 3 bore APOE ε4 allele. The other 5 APOE ε4 allele
bearers not showing amyloid plaque formation were all
under 65 years of age at death. Patients with MND,
MND + FTD and FTD, collectively, were therefore sig-
nificantly more likely to show amyloid in the brains if
they died after the age of 65 years (χ2 = 11.7, p < 0.001).
Indeed, all except 1 of the 10 patients with MND,
MND + FTD and FTD, collectively, who showed both
amyloid and tau in their brains were over 65 years of
age at death, and of these 9 patients, 6 were bearers
of APOE ε4 allele. Hence, patients with MND, MND+
FTD and FTD most likely to show amyloid in their brains
were those who died after the age of 65 years and bore
APOE ε4 allele.
Discussion
Although the presence of some degree of tau patho-
logical changes in patients with ALS/MND [16, 29] or
FTLD [29] has been anecdotally reported, there has been
only little work where this has been systematically stud-
ied. Using novel antibodies to tau phosphorylated at
Ser208/210, Thr175 and Thr217, Yang and Strong [36]
investigated 5 MND patients with cognitive impairment
(ALSci) and 5 others with no cognitive impairment
(ALS) (as defined by Strong et al [31]). In the ALS
patients, they observed a limited number of intraneuro-
nal tau inclusions (neurofibrillary tangles) and neuropil
threads in temporal lobe structures, mostly in entorhinal
cortex, and amygdala, less so in hippocampus and
frontal and cingulate cortex in 1–3/5 cases, which were
broadly similarly immunoreactive with all 3 antibodies.
A similar type of tau pathology was seen in the entorhi-
nal cortex, amygdala and hippocampus in the 5 ALSci
cases, but in these the frontal cortex and cingulate gyrus
were more often involved (usually in 3–5/5 cases).
Again, the level of immunostaining with all 3 antibodies
was roughly similar. Although, Yang and Strong [36] did
not perform Braak staging for neuronal tau, from their
descriptions it can be inferred that cases of ALS were at
Braak stages 0/I, whereas those with ALSci may have
been at Braak stages III-IV.
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In the present study we have shown there to be ‘sig-
nificant’ neuronal tau pathology in 59 % patients with
MND, 44 % patients with FTD +MND and 44 % pa-
tients with FTD, whereas some degree of amyloid path-
ology was present in only 34 % patients with MND, 7 %
patients with FTD +MND and 26 % patients with FTD.
In this study, we have also employed the same antibodies
to tau phosphorylated at Thr175 and Thr217, along with
commercial AT8 antibody, and have supplemented these
observations with 3-R and 4-R tau immunostaining and
western blotting, on selected patients. Analysis of the
patterns of tau and amyloid plaque pathologies sug-
gested several ‘profiles’ to be present.
Firstly, in those 9 patients with MND (patients #18–
26), 6 with MND + FTD (patients #51–56) and 6 with
FTD (patients #71–76), where minimal temporal lobe
tau (Braak stage 0-I/I) but no amyloid plaque patholo-
gies were present, the tau changes might be simply con-
sidered to be ‘age-related’ and unlikely to be associated
with (early stage) Alzheimer’s disease, given the lack of
amyloid pathology [23]. Nonetheless, the concept of Pri-
mary Age-Related Tauopathy (PART) has been pro-
moted to describe cases where tau pathology, especially
medial temporal lobe tau, occurs in the complete ab-
sence of amyloid plaque deposition (Thal phase zero), or
at least minimal amounts [10, 15]. Such a designate
would encompass pathologies formerly described as ’tan-
gle only dementia’, or ‘tangle predominant senile demen-
tia’ where extensive tau pathology, but usually not
beyond Braak stage III-IV, is seen (sometimes) in the
presence of an identifiable dementia or cognitive impair-
ment [5, 15, 35]. Unfortunately, because of the low level
of tau pathology present, and despite a 5-fold enrich-
ment of sample, it was not possible to demonstrate any
tau banding patterns on western blot in either frontal or
temporal cortex in any of patients which might illumin-
ate the molecular nature of this staining. Nonetheless,
the neurofibrillary changes present were detected by
both 3-R and 4-R tau immunostaining, as is typical for
Alzheimer’s disease, and as has been reported in PART
by others [15]. Consequently, these 21 patients with
limited temporal lobe tau pathology, but no amyloid,
might alternatively be considered to fall under the
‘umbrella’ of PART.
Secondly, in those 10 patients with MND (patients #
27–36), 1 with FTD +MND (patient #57) and 3 with
FTD (patients #77–79), where both tau AND amyloid
pathology was present, the pattern and distribution of
tau pathology within the temporal lobe (and other
regions when present) was of the type associated with
Alzheimer’s disease, ie neurofibrillary tangles, neuropil
threads and occasionally neuritic plaques. However, in
most instances the extent of neurofibrillary pathology
clearly fell well short of that associated with fully
developed Alzheimer’s disease, and none of the patients
met pathological diagnostic criteria for (a high probabil-
ity of ) Alzheimer’s disease [23]. For the most part, this
can be interpreted as ‘incidental’ and probably-age related,
being of that type commonly seen in many older healthy,
individuals and considered unlikely to generate significant
clinical dysfunction [8]. Nonetheless, three patients did
meet pathological criteria for an intermediate likeli-
hood of Alzheimer’s disease [23]. One of these pa-
tients (patient#36) showed mild cognitive impairment,
another (patient #35) also had isocortical DLB and
was clinically demented, and the third (patient #79)
had FTD (with PNFA). Where tau pathology was suf-
ficiently extensive to make western blotting possible
(in patients #30 and 35) this produced a banding pat-
tern consistent with Alzheimer’s disease, and neuro-
fibrillary changes were detected by 3-R and 4-R tau
immunostaining, again consistent with (an evolving)
Alzheimer’s disease pathology.
Thirdly, in 4 patients (patients #37–40) an unusual
pattern of tau pathology (fine or coarse granules) was
seen, which was only demonstrated by pThr175 immuno-
staining, and not at all with pThr217 or AT8 antibodies.
Such changes were most prominent in frontal cortex,
being uncommon in, or absent from, temporal cortex.
None of the 4 patients were considered to have shown
overt clinical evidence of cognitive impairment, although
this had not been formally assessed in any of the 4 pa-
tients. Again, despite 5-fold enrichment of sample, it
was not possible in patients #37–39 to demonstrate on
western blot from the frontal cortex any tau banding
pattern relevant to the pThr175 tau pathology seen histo-
logically in the frontal cortex of these patients. However,
in patient #40 a pattern resembling that of Alzheimer’s
disease was seen in the temporal cortex sample consist-
ent with the presence of limited tau neurofibrillary
tangle formation and mild amyloid deposition on
histological inspection. Immunostaining for both 3-R
and 4-R tau showed occasional nerve cells in frontal
cortex to be immunoreactive for both, again consist-
ent with the presence of mild Alzheimer-type path-
ology within temporal lobe only. Consequently, the
nosology, and significance, of the pThr175 frontal cor-
tical tau pathology, of these cases (including case
#40) presently remains uncertain.
Yang and Strong reported the presence of tau-
immunoreactive astrocytes, especially within the frontal
cortex, amygdala and entorhinal cortex, that were gener-
ally much more common in ALSci than ALS, and were
more strongly detected using pThr217 antibody than
pThr175 or pSer208/210 antibodies [36]. From descriptions
presented, it is difficult to ascertain precisely just how
common this glial cell pathology might have been, but
from inspection of the tabulated data, it would appear to
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be sparse in any region of brain in ALS in most patients,
being relatively frequent only in isolated individuals (in
1/5 studied). In ALSci tau positive glial cells were seen
in a greater proportion of patients (at least in frontal
cortex), but were not seemingly present in any greater
numbers than in ALS alone. In the present study, tau
positive astrocytes cells were not, or only very rarely,
seen irrespective of diagnosis, these being equally de-
tected by AT8, pThr175 and pThr217 antibodies. The rea-
sons for this discrepancy are not clear, but may relate to
case selection or tissue processing. In the present study,
cases of MND, FTD +MND and FTD were unselected,
representing consecutive cases entering Manchester
Brain Bank from 1986 onwards. The MND patients, with
the exception of two, were not thought to exhibit
cognitive change, although in the absence of formal
neuropsychological assessments, the presence of subtle
changes cannot be excluded. Patients with FTD +MND
and FTD had undergone extensive neuropsychological
assessment and their pattern of behavioural, personality
and cognitive change was well documented [30, 34]. The
degree of clinical and pathological overlap between the
ALSci cases reported by Yang and Strong [36] and those
in the current series is open to debate.
Hence, in the present study, we were able to substantiate
Yang and Strong’s findings of neuronal/neuritic tau path-
ology in over half of patients with MND, this also being
similarly present in around 40 % of FTD +MND and
FTD. The tau pathology was of a type similar to that seen
in Alzheimer’s disease, albeit to a much more limited ex-
tent, usually confined to temporal lobe structures, some-
times restricted to entorhinal cortex. The clear inference
from present observations is that when cognitive impair-
ment does occur in MND, this is most likely to be associ-
ated with Alzheimer’s disease pathology, particularly
involving medial temporal lobe structures. Exacerbation of
this extent of pathology in ALS/MND might explain the
cognitive deficits seen in patients with ALSci reported by
Yang and Strong [36].
Conclusions
Nonetheless, if it were to be accepted that FTD, FTD +
MND and MND exist on a continuum, and that the clin-
ical combination of FTD +MND can be driven in either
direction from FTD or MND through a common patho-
genetic pathway, then it might have been anticipated that
a neuronal and/or glial cell tauopathy, similar to that re-
ported by Yang and Strong [36], would have been (more
widely) present in our FTD+MND, even more so in FTD,
than MND alone. In fact, the extent of neuronal tau in
FTD+MND, in line with that seen in FTD, was not
greater, but in fact less, than that seen in MND alone, and
a glial cell tau pathology specifically detected by pThr217
immunostaining in MND [36] was not seen in either FTD
+MND or FTD alone. Consequently, present data sug-
gests that the route to cognitive impairment in at least
some cases of MND (ie ALSci) may be dissimilar to that
seen in FTD (and leading to FTD+MND), which is most
likely associated with TDP-43 proteinopathy in both con-
ditions, thereby challenging the notion that all cognitive
changes in FTD, FTD+MND and MND exist on a
common pathological continuum. The presence of tau
pathology in MND patients should not be considered a
marker of a person’s likelihood of developing FTD.
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